Royalty Pharma plc

NASDAQ•RPRX

CEO: Mr. Pablo Gerardo Legorreta

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2020-06-16

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Contact Information

110 East 59th Street, New York, NY, 10022, United States

212-883-0200

www.royaltypharma.com

Market Cap

$21.42B

P/E (TTM)

28.0

18.2

Dividend Yield

1.8%

52W High

$50.00

52W Low

$31.58

52W Range

100%

Rank25Top 11.9%

5.6

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Average • 5.6 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$621.99M+0.00%

4-Quarter Trend

EPS

$0.64+0.00%

4-Quarter Trend

FCF

$827.15M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Portfolio Receipts Growth Strong Portfolio Receipts reached $3.254B in 2025, marking a 16.2% increase over 2024 performance, showing strong cash generation.

Total Revenue Increased Modestly Total income and other revenues grew 5.1% to $2.378B in 2025, primarily driven by income from financial royalty assets.

Net Income Declined 10.2% Net income attributable to Royalty Pharma plc fell to $770.9M in 2025, down 10.2% from the prior year results.

Significant Capital Deployment Deployed $2.6B cash in 2025 to acquire royalties, milestones, and contractual receipts, supporting future growth objectives.

Risk Factors

Sales Risks Impact Royalties Product sales risks, including pricing pressures and competition, may reduce or cease royalty payments received from marketers.

Royalty Market Growth Uncertainty Royalty market may not sustain past growth rates, potentially preventing capital deployment at targeted rates for acquisitions.

Marketer Operations Outside Control Marketers control product commercialization, regulatory compliance, and manufacturing, directly impacting realized cash flow.

Development Stage Acquisition Risks Development-stage acquisitions face regulatory approval uncertainty, potentially leading to non-cash impairment write-downs if trials fail.

Outlook

Focus on Capital Allocation Management prioritizes dynamic capital allocation framework to fund new royalty acquisitions and return capital via dividends/repurchases.

Share Repurchase Program Active $1.8B remains available under the new share repurchase program authorized by the board through June 2027.

Continue Funding Innovation Strategy Growth strategy focuses on partnering across the value chain to fund innovation via third-party royalties and synthetic royalties.

Internalization Benefits Realization Realizing anticipated benefits from the May 2025 Internalization may be exposed to new operational costs and risks.

Peer Comparison

Revenue (TTM)

FMS

$22.15B

+1.5%

THC

$21.31B

+3.1%

SNN

$11.99B

+11.4%

Gross Margin (Latest Quarter)

RPRX

100.0%

+0.0pp

EXEL

95.6%

+0.1pp

GMAB

92.3%

-0.7pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
UTHR	$25.79B	19.5	19.3%	0.0%
RPRX	$21.42B	28.0	11.9%	45.6%
ROIV	$21.35B	-25.7	-18.3%	4.0%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

3.1%

Moderate Growth

4Q Net Income CAGR

-3.5%

Stable Profitability

Cash Flow Stability

100%

Strong Cash Flow

Deep Research

Next earnings:May 6, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data